Fellowships, Grants, & Awards.Planning Grants for Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Epidemiologic and Intervention Studies intervention studies, n.pl the epidemiologic investigations designed to test a hypothesized cause and effect relation by modifying the supposed causal factor(s) in the study population. The National Institute on Aging The National Institute on Aging is a division of the U.S. National Institutes of Health, located in Bethesda, Maryland. Formed in 1974, NIA's mission is to improve the health and well-being of older Americans through research. It is the primary U.S. and the NIEHS NIEHS National Institute of Environmental Health Sciences (NIH, DHHS) will provide grant support for planning and protocol development of biomedical epidemiologic and intervention studies in research areas supported by the Geriatrics geriatrics (jĕrēă`trĭks), the branch of medicine concerned with conditions and diseases of the aged. Many disabilities in old age are caused by or related to the deterioration of the circulatory system (see arteriosclerosis), e.g. Program. Applications may be submitted by foreign and domestic for-profit and nonprofit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local government, and eligible agencies of the federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. The mechanism of support will be the NIA NIA National Institute on Aging (NIH) NIA National Indoor Arena (UK) NIA National Intelligence Agency (South Africa and Thailand) NIA National Institute of Accountants Planning Grant (R21), which will provide up to $150,000 in direct costs for one year. The award cannot be renewed. Applicants should note that NIA or NIEHS funding of a planning grant does not imply a commitment by NIA or NIEHS to fund the proposed full-scale study, nor even to accept a subsequent application for such a study. Applications should he submitted on Application Form PHS (Personal Handyphone System) A TDMA-based cellular phone system introduced in Japan in mid-1995. Operating in the 1880-1930 MHz band, PHS uses microcells that cover an area only 100 to 500 meters in diameter, resulting in lower equipment costs but requiring more base 398. Application kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural extramural /ex·tra·mu·ral/ (-mur´il) situated or occurring outside the wall of an organ or structure. extramural situated or occurring outside the wall of an organ or structure. Outreach and Information Resources (1) The data and information assets of an organization, department or unit. See data administration. (2) Another name for the Information Systems (IS) or Information Technology (IT) department. See IT. , NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. , 6701 Rockledge Drive, MSC (1) (MSC.Software Corporation, Santa Ana, CA, www.mscsoftware.com) Founded in 1963 by Richard H. MacNeal and Robert G. Schwendler, MSC is the world's largest provider of mechanical computer aided engineering (MCAE) strategies, simulation software and services. 7910, Bethesda, MD 20892-7910 USA, by calling 301-435-0714, or by e-mailing grantsinfo@ nih.gov. Applications ate also available on the Internet at http://grants.nih.gov/grants/forms.htm. Contact: Evan C. Hadley, Associate Director, Geriatrics, NIA, 7201 Wisconsin Avenue, Suite 3E327, MSC 9205, Bethesda, MD 20892-9205 USA, fax: 301-402-1784, e-mail: hadleye@exmur. nia.nih.gov; or Gwen W. Collman, Program Administrator, Environmental and Molecular Epidemiology molecular epidemiology Molecular medicine An evolving field that combines the tools of standard epidemiology–case studies, questionnaires and monitoring of exposure to external factors with the tools of molecular biology–eg, restriction endonucleases, , NIEHS, PO Box 12233, Research Triangle Park Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , NC 27709 USA, 919-541-4980, fax: 919-541-4937, e-mail: collman@niehs.nih.gov. Reference: PA No. PA-99-145 Cancer Education Grants are available from the National Cancer Institute to support the development and implementation of curriculum-dependent programs to train predoctoral pre·doc·tor·al adj. Of, relating to, or engaged in advanced academic study in preparation for a doctorate: predoctoral course work; a predoctoral student. and postdoctoral post·doc·tor·al also post·doc·tor·ate adj. Of, relating to, or engaged in academic study beyond the level of a doctoral degree. Noun 1. candidates in cancer research settings that are highly interdisciplinary and collaborative. This program is particularly applicable to cancer prevention and control, epidemiology, nutrition, and the behavioral and population sciences. However, it should also be considered by other highly interdisciplinary areas of research (such as imaging and molecular diagnosis) that will require sustained leadership, dedicated faculty time, specialized curriculum development, interdisciplinary research environments, and more than one mentor per program participant to achieve their education and research career development objectives. Application deadlines include June 1, October 1, and February 1. Applicants must use Application Form PHS 398. Application kits are available by calling 301-437-0714, by e-mailing grantsinfo@nih.gov, or on the Internet at http://grants.nih.gov/grants/ forms.htm. Contact: Lisa Begg, Cancer Training Branch, NCI See Liberate. , 6116 Executive Boulevard, Suite 7011, MSC 8346, Bethesda, MD 20892-8346 USA, fax: 301-402-4472, e-mail: begg1@mail.nih.gov. Reference: PA No. PAR-00-064 Innovative Grants on Immune Tolerance Immune or immunological tolerance is the process by which the immune system does not attack an antigen. It occurs in three forms: central tolerance, peripheral tolerance and acquired tolerance. The National Institute of Allergy and Infectious Diseases infectious diseases: see communicable diseases. and the National Institute of Diabetes and Digestive and Kidney Diseases About NIDDK The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), of the U.S. National Institutes of Health, conducts and supports research on many of the most serious diseases affecting public health. invite applications for exploratory/developmental research project grants to support novel work on the molecular mechanisms and applications of antigen-specific immune tolerance, which is the selective and long-term inactivation inactivation /in·ac·ti·va·tion/ (in-ak?ti-va´shun) the destruction of biological activity, as of a virus, by the action of heat or other agent. of immune responses. The projects should involve a high degree of innovation and have a clearly articulated potential to improve understanding of immune tolerance. Investigators new to immune tolerance are particularly encouraged to develop projects in this area. Research projects will be supported by the exploratory/developmental research grant mechanism, which provides the resources to carry out preliminary feasibility tests for new research hypotheses. Letters of intent are requested by 1 August 2000 for applications that are due 14 September 2000. The goal of this initiative is to support truly innovative projects on immune tolerance and to encourage investigators working in other areas of research to bring novel perspectives and expertise to this field. High-risk, high-impact projects that have the potential to significantly increase our understanding of the mechanisms that induce long-lived, antigen-specific immune tolerance for application to human disease are sought. Studies relevant to the etiology and/or treatment of type 1 diabetes mellitus type 1 diabetes mellitus Brittle DM, insulin-dependent DM, juvenile-onset DM Endocrinology A severe form of DM caused by ↓ endogenous insulin production by the pancreas, which comprises +– 10% of DM Clinical Extreme hyperglycemia, lability of glucose are of particular interest to the NIDDK NIDDK National Institute of Diabetes and Digestive and Kidney Diseases . Studies on HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome are excluded from this program. Within a two- or three-year funding period, it is expected that successful projects will yield sufficient data to support a well-planned and rigorous future grant application to continue the work by competing within the general pool of unsolicited applications. Highly innovative short-term pilot projects to evaluate new but as yet speculative concepts in immune tolerance may include, but are not limited to, research in the following areas: 1) the mechanistic basis for differences in tolerance induced by systemic versus mucosal routes, 2) identification and characterization of promising new T or B cell molecular targets for tolerance induction, 3) the parameters of tolerance induction to nonpeptide self antigens, alloantigens, or allergens, 4) the molecular events responsible for the loss of tolerance to self antigens, 5) methods to extend the duration of antigen-specific tolerance, 6) novel technologies to identify and quantitate quan·ti·tate tr.v. quan·ti·tat·ed, quan·ti·tat·ing, quan·ti·tates To determine or measure the quantity of. [Back-formation from quantitative (analysis). tolerant T or B cells, 7) development or application of cell and tissue engineering methods to predictably induce tolerance rather than immunity, 8) characterization of novel antigen-specific immunosuppressive Immunosuppressive Any agent that suppresses the immune response of an individual. Mentioned in: Antirheumatic Drugs, Graft-vs.-Host Disease, Immunosuppressant Drugs immunosuppressive 1. pertaining to or inducing immunosuppression. 2. cell types, 9) identification of mechanisms by which currently known tolerogenic biological or pharmaceutical agents induce and maintain immune tolerance, 10) development of simple and reliable assays for the identification of tolerant states in humans, and 11) development of "vaccine" strategies to induce antigen-specific tolerance to disease-related autoantigens or allergens. Contact: Helen Quill quill: see pen. , Division of Allergy, Immunology and Transplantation, NIAID NIAID National Institute of Allergy and Infectious Diseases. , 6700-B Rockledge Drive, Room 5140, Bethesda, MD 20892-7640 USA, 301-496-7551, fax: 301-402-2571, e-mail: hquill@niaid.nih.gov; or Barbara Linder, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK, Building 45, Room 5AN18A, Bethesda, MD 20892 USA, 301-594-0021, fax: 301-480-3503, e-mail: linderb@extra.niddk.nih.gov. Reference: RFA RFA right frontoanterior (position of the fetus). Radiofrequency ablation (RFA) A procedure in which radiofrequency waves are used to destroy blood vessels and tissues. Mentioned in: Prenatal Surgery AI-00-006 Beryllium-Induced Disease The goal of this proposed research initiative is to encourage and support studies that will advance our understanding of the mechanisms of chronic beryllium beryllium (bərĭl`ēəm) [from beryl ], metallic chemical element; symbol Be; at. no. 4; at. wt. 9.01218; m.p. about 1,278°C;; b.p. 2,970°C; (estimated); sp. gr. 1.85 at 20°C;; valence +2. disease (CBD (Component Based Development) Building applications with components (objects). See component software. CBD - component based development ). The participating institutes and agencies are interested in supporting research in (but not limited to) the following areas: 1) the genetic basis of beryllium sensitivity and development of CBD, 2) inflammation and granuloma granuloma /gran·u·lo·ma/ (gran?u-lo´mah) pl. granulomas, granulo´mata an imprecise term for (1) any small nodular delimited aggregation of mononuclear inflammatory cells, or (2) such a collection of modified macrophages formation, 3) development of in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. and in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. models of beryllium sensitivity, 4) biomarkers of beryllium sensitivity and progression of CBD, and 5) methods of prevention. Applicants must use Application Form PHS 398, which has annual due dates of February 1, June 1, and October 1. Application kits are available by calling 301-437-0714, e-mailing grantsinfo@nih.gov, or on the Internet at http://grants.nih.gov/grants/forms.htm. Contact: George Malindzak, Organs and Systems Toxicology Branch, NIEHS, PO Box 12233, MD EC-23, Research Triangle Park, NC 27709 USA, 919-541-3289, fax: 919-541-5064, e-mail: malindzak@niehs.nih.gov; Robert Musson, Division of Lung Biology and Disease Program, National Heart, Lung, and Blood Institute National Heart, Lung, and Blood Institute, n.pr established in 1948, this division of the National Institutes of Health is responsible for research and education on cardiovascular, pulmonary, systemic diseases, and sleep disorders. , 6701 Rockledge Drive, Room 10108, MSC 7952, Bethesda, MD 20892-7952 USA, 301-435-0222, fax: 301-480-3557, e-mail: mussonr@gwgate.nhlbi.nih.gov; Roy M. Fleming, National Institute for Occupational Safety and Health National Institute for Occupational Safety and Health, n.pr an institute of the Centers for Disease Control and Prevention that is responsible for assuring safe and healthful working conditions and for developing standards of safety and health. , Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center. , 1600 Clifton Road Clifton Road is main street in Clifton neighborhood of Saddar Town in Karachi, Sindh, Pakistan. Its name dates from the British Colonial rule, and its market is posh areas of Karachi. NE, Building 1, Room 3053, MS-D30, Atlanta, GA 30333 USA, 404-639-3343, fax: 404-639-4616, e-mail: rmf2@cdc.gov; or Paul J. Seligman, Deputy Assistant Secretary, Office of Health Studies, Department of Energy, 19901 Germantown Road, Germantown, MD 20874 USA, 301-903-5926, fax: 301-903-3445, e-mail: paul.seligman@eh.doe.gov. Reference: PA No. PA-99-075 Exploratory Grants for Genomic Imprinting Genomic imprinting is a genetic phenomenon by which certain genes are expressed in a parent of origin-specific manner. Forms of genomic imprinting have been demonstrated in insects, mammals and flowering plants. and Environmental Disease Susceptibility The NIEHS invites research grant applications from interested investigators to conduct timely, innovative, and mechanistic research on the importance of genomic imprinting in determining susceptibility to environmentally induced diseases through a program of exploratory investigator-initiated R21 grants. The exploratory/developmental (R21) grant mechanism is used for pilot projects or feasibility studies to support creative, novel, high risk/high pay-off research that may produce innovative advances in science. This announcement is to encourage applications from individuals who ale interested in testing novel or conceptually creative ideas to understand the potential role that environmental agents play in causing epigenetic epigenetic /epi·ge·net·ic/ (-je-net´ik) 1. pertaining to epigenesis. 2. altering the activity of genes without changing their structure. changes in the DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. that can alter imprint gene expression, thereby resulting in a multitude of genetic diseases including cancer and neurobehavioral disorders. The final receipt date will be 1 October 2002. Applications may be submitted by domestic for-profit and nonprofit organizations such as universities, colleges, hospitals, laboratories, units of state and local Planning Grants for Biomedical Epidemiologic and Intervention Studies The National Institute on Aging and the NIEHS will provide grant support for planning and protocol development of biomedical epidemiologic and intervention studies in research areas supported by the Geriatrics Program. Applications may be submitted by foreign and domestic for-profit and nonprofit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local government, and eligible agencies of the federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. The mechanism of support will be the NIA Planning Grant (R21), which will provide up to $150,000 in direct costs for one year. The award cannot be renewed. Applicants should note that NIA or NIEHS funding of a planning grant does not imply a commitment by NIA or NIEHS to fund the proposed full-scale study, nor even to accept a subsequent application for such a study. Applications should be submitted on Application Form PHS 398. Application kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, NIH, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910 USA, by calling 301-435-0714, or by e-mailing grantsinfo@ nih.gov. Applications are also available on the Internet at http://grants.nih.gov/grants/forms.htm. Contact: Evan C. Hadley, Associate Director, Geriatrics, NIA, 7201 Wisconsin Avenue, Suite 3E327, MSC 9205, Bethesda, MD 20892-9205 USA, fax: 301-402-1784, e-mail: hadleye@exmur. nia.nih.gov; or Gwen W. Collman, Program Administrator, Environmental and Molecular Epidemiology, NIEHS, PO Box 12233, Research Triangle Park, NC 27709 USA, 919-541-4980, fax: 919-541-4937, e-mail: collman@niehs.nih.gov. Reference: PA No. PA-99-145 Cancer Education Grants are available from the National Cancer Institute to support the development and implementation of curriculum-dependent programs to train predoctoral and postdoctoral candidates in cancer research settings that are highly interdisciplinary and collaborative. This program is particularly applicable to cancer prevention and control, epidemiology, nutrition, and the behavioral and population sciences. However, it should also be considered by other highly interdisciplinary areas of research (such as imaging and molecular diagnosis) that will require sustained leadership, dedicated faculty time, specialized curriculum development, interdisciplinary research environments, and more than one mentor per program participant to achieve their education and research career development objectives. Application deadlines include June 1, October 1, and February 1. Applicants must use Application Form PHS 398. Application kits are available by calling 301-437-0714, by e-mailing grantsinfo@nih.gov, or on the Internet at http://grants.nih.gov/grants/ forms.htm. Contact: Lisa Begg, Cancer Training Branch, NCI, 6116 Executive Boulevard, Suite 7011, MSC 8346, Bethesda, MD 20892-8346 USA, fax: 301-402-4472, e-mail: begg1@mail.nih.gov. Reference: PA No. PAR-00-064 Innovative Grants on Immune Tolerance The National Institute of Allergy and Infectious Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases invite applications for exploratory/developmental research project grants to support novel work on the molecular mechanisms and applications of antigen-specific immune tolerance, which is the selective and long-term inactivation of immune responses. The projects should involve a high degree of innovation and have a clearly articulated potential to improve understanding of immune tolerance. Investigators new to immune tolerance are particularly encouraged to develop projects in this area. Research projects will be supported by the exploratory/developmental research grant mechanism, which provides the resources to carry out preliminary feasibility tests for new research hypotheses. Letters of intent are requested by 1 August 2000 for applications that are due 14 September 2000. The goal of this initiative is to support truly innovative projects on immune tolerance and to encourage investigators working in other areas of research to bring novel perspectives and expertise to this field. High-risk, high-impact projects that have the potential to significantly increase our understanding of the mechanisms that induce long-lived, antigen-specific immune tolerance for application to human disease are sought. Studies relevant to the etiology and/or treatment of type 1 diabetes mellitus are of particular interest to the NIDDK. Studies on HIV/AIDS are excluded from this program. Within a two- or three-year funding period, it is expected that successful projects will yield sufficient data to support a well-planned and rigorous future grant application to continue the work by competing within the general pool of unsolicited applications. Highly innovative short-term pilot projects to evaluate new but as yet speculative concepts in immune tolerance may include, but are not limited to, research in the following areas: 1) the mechanistic basis for differences in tolerance induced by systemic versus mucosal routes, 2) identification and characterization of promising new T or B cell molecular targets for tolerance induction, 3) the parameters of tolerance induction to nonpeptide self antigens, alloantigens, or allergens, 4) the molecular events responsible for the loss of tolerance to self antigens, 5) methods to extend the duration of antigen-specific tolerance, 6) novel technologies to identify and quantitate tolerant T or B cells, 7) development or application of cell and tissue engineering methods to predictably induce tolerance rather than immunity, 8) characterization of novel antigen-specific immunosuppressive cell types, 9) identification of mechanisms by which currently known tolerogenic biological or pharmaceutical agents induce and maintain immune tolerance, 10) development of simple and reliable assays for the identification of tolerant states in humans, and 11) development of"vaccine" strategies to induce antigen-specific tolerance to disease-related autoantigens or allergens. Contact: Helen Quill, Division of Allergy, Immunology and Transplantation, NIAID, 6700-B Rockledge Drive, Room 5140, Bethesda, MD 20892-7640 USA, 301-496-7551, fax: 301-402-2571, e-mail: hquill@niaid.nih.gov; or Barbara Linder, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK, Building 45, Room 5AN18A, Bethesda, MD 20892 USA, 301-594-0021, fax: 301-480-3503, e-mail: linderb@extra.niddk.nih.gov. Reference: RFA AI-00-006 Beryllium-Induced Disease The goal of this proposed research initiative is to encourage and support studies that will advance our understanding of the mechanisms of chronic beryllium disease (CBD). The participating institutes and agencies are interested in supporting research in (but not limited to) the following areas: 1) the genetic basis of beryllium sensitivity and development of CBD, 2) inflammation and granuloma formation, 3) development of in vitro and in vivo models of beryllium sensitivity, 4) biomarkers of beryllium sensitivity and progression of CBD, and 5) methods of prevention. Applicants must use Application Form PHS 398, which has annual due dates of February 1, June 1, and October 1. Application kits are available by calling 301-437-0714, e-mailing grantsinfo@nih.gov, or on the Internet at http://grants.nih.gov/grants/forms.htm. Contact: George Malindzak, Organs and Systems Toxicology Branch, NIEHS, PO Box 12233, MD EC-23, Research Triangle Park, NC 27709 USA, 919-541-3289, fax: 919-541-5064, e-mail: malindzak@niehs.nih.gov; Robert Musson, Division of Lung Biology and Disease Program, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 10108, MSC 7952, Bethesda, MD 20892-7952 USA, 301-435-0222, fax: 301-480-3557, e-mail: mussonr@gwgate.nhlbi.nih.gov; Roy M. Fleming, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Building 1, Room 3053, MS-D30, Atlanta, GA 30333 USA, 404-639-3343, fax: 404-639-4616, e-mail: rmf2@cdc.gov; or Paul J. Seligman, Deputy Assistant Secretary, Office of Health Studies, Department of Energy, 19901 Germantown Road, Germantown, MD 20874 USA, 301-903-5926, fax: 301-903-3445, e-mail: paul.seligman@eh.doe.gov. Reference: PA No. PA-99-075 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion